Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: An assertion based on comprehensive, critical analysis: Part I

American Journal of Dermatopathology

Volumn 25, Issue 5, 2003, Pages 399-417

  Medalie, N S ^b   Ackerman, A Bernard ^a  

^a ACKERMAN ACADEMY OF DERMATOPATHOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

CANCER ADJUVANT THERAPY; CELL MIGRATION; DIAGNOSTIC VALUE; HUMAN; LITERATURE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL PRACTICE; MELANOMA; MELANOMA CELL; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; STANDARD;

FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEDICAL ONCOLOGY; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 0141676889     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200310000-00006     Document Type: Review

References (62)

1. Snow H. Abstract of a lecture on melanotic cancerous disease. Lancet. 1892:872-874.
2. Adair FE. Treatment of melanoma: report of four hundred cases. Surg Gynec & Obst. 1936;62:400-409.
3. Pack GT, Scharnagel I, Morfit M. Principle of Excision and Dissection in Continuity for Primary and Metastatic Melanoma of Skin Surgery. 1945; 17:849-866.
4. Meyer HW, Gumport SL. Malignant melanoma: appraisal of the disease and analysis of one hundred and five cases. Ann Surg. 1953;138:643-660.
5. Jackson R. Persistent fallacies concerning dissemination of malignant melanoma. Can J Surg. 1970;13:331-332.
6. Handley WS. The Hunterian lectures on the pathology of melanotic growths in relation to their operative treatment. Lancet. 1907;1:927-933.
7. Thurston OG. Lymph-node dissection for melanoma. Can J Surg. 1970; 13:332-333.
8. Breslow A. Tumor thickness, level of invasion and node dissection in Stage I cutaneous melanoma. Ann Surg. 1976;182:572-575.
9. Breslow A. Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
10. Balch CM, Murad TM, Soong SJ, et al. Tumor thickness as a guide to surgical management of clinical Stage I melanoma patients. Cancer. 1979;43:883-888.
11. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma II. Prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979;86:343-351.
12. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1786 patients with localized(stage I)melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg. 1982;196:677-684.
13. Milton GW, Shaw HM, McCarthy WH, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg. 1982;69:108-111.
14. McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection in 2347 patients with clinical stage I malignant melanoma. Surg Gynec & Obst. 1985;161:575-580.
15. Crowley NJ, Seigler HF. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer. 1990; 66:2522-2527.
16. Drepper H, Kohler CO, Bastian B, et al. Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer. 1993;72:741-749.
17. Veronesi U, Adamus J, Bandiera DC, et al. Stage I melanoma of the limbs. Immediate versus delayed node dissection. Tumori. 1980;66:373-396.
18. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420-2430.
19. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer. 1978;41:948-956.
20. Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697-705.
21. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-263; 1996;discussion 263-266.
22. Balch CM, Soong S, Ross MI, et al. Long-term results of a multiinstitutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87-97.
23. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351:793-796.
24. Cady B. Prophylactic lymph node dissection in melanoma: Does it help? J Clin Oncol. 1988;6:2-4.
25. Cady B. Lymph node metastases: Indicators, but not governors of survival. Arch Surg. 1984;119:1067-1072.
26. Scott RN, McKay AJ. Elective lymph node dissection in the management of malignant melanoma. Br J Surg. 1993;80:284-288.
27. Reintgen D, Fenske N, Cruse CW, et al. Response Dermatol Surg. 2001; 27:426-427.
28. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;XLVI:1-19.
29. th ed. Washington: Mosby; 1912:1989.
30. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol. 1988;12:612-618.
31. Cabanas RN. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456-466.
32. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
33. Gibbs JF, Huang PP, Zhang PJ, et al. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann Surg Oncol. 1999;6:699-704.
34. Koopal SA, Tiebosch AT, Albertus Piers D, et al. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer. 2000;89:1720-1725.
35. Tanis PJ, Boom RP, Koops HS, et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol. 2001;8:222-226.
36. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-2260.
37. Gadd MA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134: 381-387.
38. Clary BM, Mann B, Brady MS, et al. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol. 2001;8:328-337.
39. Cochran AJ. Melanoma metastases through the lymphatic system. Surg Clin North Am. 2000;80:1683-1693.
40. Cochran AJ. The Pathologist's role in sentinel lymph node evaluations. Semin Nucl Med. 2000;30:11-17.
41. Heller R, Becker J, Wasselle J, et al. Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg. 1991;126:1455-1459; discussion 1459-1460.
42. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. 1998;280:1410-1415.
43. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 1999;17:3238-3244.
44. Lukowsky A, Bellmann B, Ringk A, et al. Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J Invest Dermatol. 1999;113:554-559.
45. Blaheta HJ, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000; 114:637-642.
46. Palmieri G, Ascierto PA, Cossu A, et al. Melanoma Cooperative Group. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J Clin Oncol. 2001;19:1437-1443.
47. Blaheta HJ, Sotlar K, Breuninger H, et al. Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma? Melanoma Res. 2001;11:57-63.
48. Haagensen CD, Feind CR, Herter FP, et al. The Lymphatics in Cancer. Philadelphia; W.B. Saunders Co.; 1972:1-13.
49. Sherman AI, Ter-Pogassian M, Tocus EC. Lymph node concentration of radioactive colloidal gold following interstitial injection. Cancer. 1953;6:1238.
50. Norman J, Cruse CW, Espinosa C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162:432-437.
51. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637-641.
52. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230:453-463; discussion 463-465.
53. Jansen L, Nieweg OE, Peterse JL, et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. 2000;87:484-489.
54. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I of II melanoma patients. J Clin Oncol. 1999;17:976-983.
55. Alex JC, Krag DN. Gamma probe guided localization of lymph nodes. Surg Oncol. 1993;2:137-143.
56. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001;8:192-197.
57. Uren RF, Howman-Giles R, Thompson JF, et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg. 2000;135: 1168-1172.
58. Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol. 1999;6:442-449.
59. Leong SPL. The role of sentinel lymph nodes in malignant melanoma. Surg Clin North Am. 2000;80:1741-1757.
60. Bachter D, Michl C, Buchels H, et al. The predictive value of the sentinel lymph node in malignant melanomas. Recent Results Cancer Res. 2001; 158:129-136.
61. Dessureault S, Soong SJ, Ross MI, et al. American Joint Committee on Cancer (AJCC) Melanoma Staging Committee. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001;8:766-770.
62. Kelley SW, Cockerell CJ. Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: a proposal. J Am Acad Dermatol. 2000;42:527-530.